deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02681055

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia

Sponsor: MediciNova

Conditions Hypercholesterolemia Hypertriglyceridemia Non-alcoholic Fatty Liver Disease Non-alcoholic Steatohepatitis
Interventions MN-001
Updated 16 times since 2017 Last updated: Feb 17, 2023 Started: Mar 31, 2016 Primary completion: May 30, 2018 Completion: Oct 1, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hypercholesterolemia and Hypertriglyceridemia and is currently completed. MediciNova leads this study, which shows 16 recorded versions since 2016 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Feb 2018 · 5 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Nov 2019 · 9 months · monthly snapshot~Nov 2019 – ~Jun 2020 · 7 months · monthly snapshot~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Apr 2022 — Apr 2023 [monthly]

    Completed PHASE2

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

▶ Show 11 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jun 2020 — Nov 2020 [monthly]

    Completed PHASE2

  3. Nov 2019 — Jun 2020 [monthly]

    Completed PHASE2

  4. Feb 2019 — Nov 2019 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Aug 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  8. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  9. Sep 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

  10. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MediciNova
Data source: MediciNova

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations